State-by-State GLP-1 Prescribing Rules: Where Telehealth Hits Legal Walls in 2026
The business model that scaled in 2022–2024 — direct-to-consumer telehealth platforms shipping compounded semaglutide nationwide for $200–$400 per month — was always structurally fragile. In 2026, every one of its legal assumptions is under attack. State medical boards in New York, California, Texas, and Florida have taken disciplinary action against telehealth-only weight-loss prescribers. The DOJ has investigated platforms whose prescribing patterns fell short of bona fide examinations.1,2
The Core Legal Problem
GLP-1 medications are not controlled substances — they're not scheduled under the DEA Controlled Substances Act. This means the Ryan Haight Act's requirement for an in-person examination before prescribing controlled substances via telehealth does not technically apply.3
However, every state has its own standard for establishing a bona fide practitioner-patient relationship before prescribing any medication. These standards vary significantly:
| Requirement | States with Stricter Rules | States with More Flexibility |
|---|---|---|
| In-person visit required for first Rx | Some interpretation in NY, certain TX boards | Most states allow video-based initial consult |
| Audio-only (phone) acceptable | Very few for initial prescribing | Some states expanded during COVID |
| Asynchronous (questionnaire-only) | Increasingly scrutinized in CA, FL, NY, TX | Some states haven't addressed directly |
| Follow-up requirements | Most states require periodic re-evaluation | Frequency varies |
Where Enforcement Is Happening
New York
The NY State Education Department, which oversees medical licensing, has investigated high-volume telehealth prescribers. Enforcement has focused on platforms where prescribers had minimal patient interaction before writing GLP-1 prescriptions.5
California
The Medical Board of California has taken action against providers associated with platforms that prescribed GLP-1s after minimal evaluation. California's standard requires that a licensee "perform an appropriate prior examination" — the definition of "appropriate" is where enforcement discretion lies.5
Texas
The Texas Medical Board has pursued disciplinary actions against GLP-1 telehealth prescribers, particularly those associated with med spa and weight-loss clinic models that lacked sufficient medical oversight.1
Florida
Florida's Board of Medicine has similarly investigated telehealth prescribing practices in the GLP-1 space.5
The DOJ Signal
The Department of Justice has signaled that high-volume cross-state telehealth prescribing without genuine practitioner-patient relationships is an enforcement priority. The February 2026 referral of Hims & Hers to the DOJ — on the same day the company launched a compounded oral semaglutide product — demonstrated the federal government's willingness to pursue platforms directly.2
What This Means for Patients
If you're using a telehealth platform for GLP-1 prescriptions, the regulatory environment does not directly create legal risk for you as a patient. The risk sits with the prescriber and the platform. However, enforcement actions can disrupt your access — if your provider is disciplined or your platform shuts down, you may need to find a new prescriber quickly.
The safest approach: use platforms that conduct genuine medical evaluations (video consultation minimum), provide ongoing follow-up care, and are transparent about their pharmacy sourcing and prescribing practices.
SOURCES
- MedSpa Standards. GLP-1 Med Spa Compliance 2026: National Guide. May 2026.
- Polsinelli PC. FDA Tightens the Belt on GLP-1 Compounding. National Law Review. February 2026.
- Ryan Haight Act. 21 USC §829(e). Telehealth prescribing requirements.
- DEA. Extension of COVID-era telehealth flexibilities. 2024-2025.
- Multiple state medical board enforcement actions. NY, CA, TX, FL. 2025-2026.